Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 2,386 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Progressive Clear all
Completed Phase 3 Interventional

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

NCT00006348
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Nausea and Vomiting, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ondansetron, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Scottsdale, Arizona • Urbana, Illinois • Des Moines, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 23, 2026, 1:30 PM EDT
Terminated Not applicable Interventional

Exercise as Adjunctive Treatment for Refractory Epilepsy

NCT04607317
View directory record Official record
Conditions
Refractory Epilepsy, Epilepsy
Interventions
Exercise program, Health Coach, Health Information
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Oct 23, 2026, 1:30 PM EDT
Recruiting Phase 1 Interventional

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

NCT07144254
View directory record Official record
Conditions
Osteosarcoma Recurrent, Osteosarcoma in Children, Relapsed Osteosarcoma, Refractory Osteosarcoma
Interventions
Tegavivint, Gemcitabine
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 1:30 PM EDT
Terminated Not applicable Interventional

Exercise Program During Chemotherapy in Metastatic Colorectal Cancer

NCT03111823
View directory record Official record
Conditions
Stage IV Colorectal Cancer
Interventions
Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration
Behavioral · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Oct 23, 2026, 1:30 PM EDT
Completed Phase 2 Interventional

Effects of Creatine and Resistance Exercise Training in People With HIV Infection

NCT00484627
View directory record Official record
Conditions
HIV Infections
Interventions
Use of creatine monohydrate (a dietary supplement), Progressive resistance exercise training
Procedure · Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2007 · Synced Oct 23, 2026, 1:30 PM EDT
Terminated Phase 2 Interventional Results available

Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001

NCT03574818
View directory record Official record
Conditions
Squamous Cell Lung Cancer
Interventions
Necitumumab-Gemcitabine-Cisplatin, Evaluation to determine if patient is a candidate to proceeed with surgical resection or not
Drug · Diagnostic Test
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 23, 2026, 1:30 PM EDT
Completed Not applicable Interventional Results available

Prospective Case Series to Refine Standalone Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

NCT05848323
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue
Interventions
4-week Relaxation Training, 4-week Behavioral Activation, 4-week Cognitive Therapy
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 23, 2026, 1:30 PM EDT
Completed Not applicable Interventional Results available

Cerebrovascular Dysregulation in Chronic Kidney Disease

NCT05571605
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Exercise, Stretching
Behavioral
Lead sponsor
University of North Texas, Denton, TX
Other
Eligibility
30 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Denton, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 23, 2026, 1:30 PM EDT
Recruiting No phase listed Observational

Study of Proteus Syndrome and Related Congenital Disorders

NCT00001403
View directory record Official record
Conditions
Proteus Syndrome, PIK3CA Related Overgrowth Spectrum
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 99 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 1:30 PM EDT
Not listed Phase 2 Interventional

Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking for Compassionate Treatment in Pediatric Patients With Progressive Keratoconus

NCT00925327
View directory record Official record
Conditions
Progressive Keratoconus
Interventions
Corneal collagen cross-linking with riboflavin/UVA light
Other
Lead sponsor
Peschke Meditrade, GmbH
Industry
Eligibility
6 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2009 · Synced Oct 23, 2026, 1:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

NCT04590326
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
Interventions
REGN5668, Cemiplimab, Ubamatamab, Sarilumab, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
13
States / cities
Duarte, California • Irvine, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 1:30 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

NCT04775485
View directory record Official record
Conditions
Low-grade Glioma, Advanced Solid Tumor
Interventions
Tovorafenib
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
6 Months to 25 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 23, 2026, 1:30 PM EDT
Recruiting Not applicable Interventional

The Fundamental Adaptive Skills Training

NCT07140718
View directory record Official record
Conditions
Fundamental Adaptive Skills Training, Relaxation and Mindfulness Training
Interventions
Fundamental Adaptive Skills Training, Relaxation and Mindfulness Training
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 23, 2026, 1:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Progressive Metabolic Adaptations to Low Intensity Exercise Training and Weight Loss

NCT01452074
View directory record Official record
Conditions
Obesity
Interventions
Exercise Training, Weight Loss with continued Exercise Training
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 23, 2026, 1:30 PM EDT
Completed Early Phase 1 Interventional

Metformin Treatment in Progressive Multiple Sclerosis

NCT05349474
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Metformin 500 Mg Oral Tablet, up to 4 tablets a day, Placebo oral tablet identical to metformin, up to 4 tablets a day
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 23, 2026, 1:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial

NCT07863180
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy(PSP)
Interventions
Tributyrin, Placebo
Drug
Lead sponsor
Prabesh Kanel
Other
Eligibility
45 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 1:30 PM EDT
Completed Phase 2 Interventional Results available

Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma

NCT01753713
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
dovitinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Manmeet Ahluwalia, MD
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 23, 2026, 1:30 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

NCT01197560
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Lenalidomide, Gemcitabine, Oxaliplatin, Rituximab, Etoposide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
13
States / cities
Burbank, California • Orlando, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 23, 2026, 1:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Breathing Interventions for Relaxation: Dosing Through Extended Exhale

NCT02870868
View directory record Official record
Conditions
Healthy Adults, Stress
Interventions
Slow breathing
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
30 Years to 60 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 23, 2026, 1:30 PM EDT
Recruiting Phase 2 Interventional

Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)

NCT07265596
View directory record Official record
Conditions
Prodromal Parkinsons Disease
Interventions
[18F] AV-133 PET Imaging
Drug
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 23, 2026, 1:30 PM EDT
Completed Phase 2 Interventional Results available

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

NCT01494662
View directory record Official record
Conditions
Breast Cancer
Interventions
HKI-272, Surgical Resection, Capecitabine, Ado-Trastuzumab Emtansine
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
18
States / cities
San Francisco, California • Washington D.C., District of Columbia • Baltimore, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 23, 2026, 1:30 PM EDT
Completed Phase 2 Interventional Results available

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

NCT00704288
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
XL184
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 23, 2026, 1:30 PM EDT
Terminated Phase 2 Interventional

Study of XL999 in Patients With Multiple Myeloma

NCT00304590
View directory record Official record
Conditions
Multiple Myeloma
Interventions
XL999
Drug
Lead sponsor
Symphony Evolution, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Joliet, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2010 · Synced Oct 23, 2026, 1:30 PM EDT
Completed Not applicable Interventional Results available

Understanding Trauma Nightmares Using In-Home Measurement

NCT03974503
View directory record Official record
Conditions
Nightmares, Stress Disorders, Post-Traumatic, Actigraphy, Respiratory Sinus Arrhythmia, Veterans
Interventions
Exposure, Relaxation, and Rescripting Therapy, Sleep and Nightmare Management
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 23, 2026, 1:30 PM EDT